Head of Early Development, Caspian Therapeutics

We are seeking a visionary executive to spearhead the formation and growth of a high-impact startup company focused on the discovery and development of menin inhibitors for diabetes and cardiometabolic indications. This is a high-growth leadership opportunity for an experienced leader ready to build a lean, science-driven organization from the ground up and accelerate the development of Caspian’s lead program, which is initially focused on generating clinical, proof-of-concept data in Type 1 diabetes.

In addition to serving as a senior executive leader, the successful candidate will oversee early clinical development of the company’s lead program, currently in IND-enabling studies, providing scientific, operational, and organizational leadership to ensure the seamless transition from research into early clinical development.

This role represents a unique opportunity to combine entrepreneurial leadership with scientific and clinical development stewardship. The successful candidate will play a central role in shaping both the company and its clinical pipeline; ultimately helping to deliver transformative therapies to patients with diabetes and cardiometabolic disease.

• Serve as the principal executive leader responsible for establishing and growing Caspian into a high-performing biotechnology company.
• Work in close partnership with the CEO and leadership team at Kura Oncology to accelerate the transition of Caspian Therapeutics from an early-stage research organization to a clinically focused development company.
• Lead creation, translation, and execution of strategic business plans, from conceptualization through early commercialization planning.
• Be instrumental in developing both short- and long-term corporate strategy, including operational planning, resource allocation, and financial management.
• Establish and maintain key external relationships with the Caspian Therapeutic board of directors, investors, partners, advisors, investigators, CROs, and other stakeholders while maintaining awareness of the competitive and regulatory landscape.

• Serve as the strategic leader for Early Clinical Development, providing guidance and oversight of integrated development plans as assets transition from discovery into clinical evaluation.
• Lead the design and execution of translational and early clinical strategies to enable efficient first-in-human and proof-of-concept studies.
• Ensure seamless transition of drug candidates from research to early clinical development through close collaboration with research, regulatory, CMC, and clinical operations functions.
• Define clinical development pathways, target product profiles, and early development milestones aligned with corporate objectives.

• As the organizational leader, be accountable for ensuring that activities within Early Clinical Development are executed within expected scope, budget, and timelines.
• Establish key milestones for development programs and provide direct leadership and organizational influence to ensure milestones are achieved or exceeded.
• Oversee clinical program planning, study design, vendor selection, and operational execution in partnership with internal and external teams.
• Closely monitor program performance and collaborate with strategic partners such as Kinexum to ensure efficient program delivery.
• Manage budgets and resources to support rapid, cost-effective advancement of the KO-7246 program and future pipeline assets.

• Take on a broad range of duties across the organization, helping to build core capabilities and infrastructure as the company scales.
• Drive cross-functional alignment between research, clinical, regulatory, and commercial planning teams.
• Provide mentorship and leadership to build a high-performing, science-driven organization.

• Advanced scientific background: PhD or MD strongly preferred.
• Significant experience in early clinical development with a strong track record of advancing programs from discovery into the clinic.
• Requires the ability to influence and lead at the executive level.
• Proven ability to build, scale, and lead organizations in a biotechnology environment.
• Demonstrated experience overseeing development plans, budgets, timelines, and cross-functional execution.
• Strong ability to prioritize multiple demands and projects.
• Has a broad background with an emphasis in clinical development, project leadership and deep understanding of clinical operations.
• Spearhead strategic business planning and execution, driving measurable growth.
• Possesses a hands-on approach and a willingness to engage in all aspects of project execution.

The base range for a Vice President is $325,000 - $380,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

#LI-RM1

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays  (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a commercial-stage biopharmaceutical company committed to discovering and developing innovative precision medicines to help patients with cancer lead better, longer lives.

Through our deep understanding of cancer biology and decades of experience in precision oncology, we are studying the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, with the goal of improving long-term clinical benefit.

Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. 

If you are a California resident, please see the attached Privacy Notice CA Privacy Notice